Awards & Recognition - VIVOS INC. (formerly AMIC) has been recognized as a leader by local, state and federal agencies.
• $1.3 million U.S. Federal grant for brachytherapy
• Leaders in Healthcare Award, Seattle Business Magazine
• Federal Laboratory Consortium Award for Excellence in Technology Transfer,
a prestigious honor recognized by the US Secretary of Energy and US Senator Murray
2015 - AMIC awarded $250,000 Life Sciences Discovery Fund Grant as Commercialization Partner
Focus: To test a novel technology for delivering high-dose radiation to solid cancers that cannot be removed surgically
Anticipated Impact: Safer, more effective treatment of radiation-resistant solid cancers
August 3, 2013 - The Secretary of Energy, Washington, D.C.
CURRENT RELEASE
Richland WA, Feb. 06, 2020 (GLOBE NEWSWIRE) --
Vivos Inc. (OTCQB: RDGL), Vivos today announced that the University of Missouri College of Veterinary Medicine will be the first Isopet® regional clinic. The
Isopet® therapy will now be included as a treatment option within their extensive veterinary cancer therapy portfolio. Following our recently completed clinical study of
Isopet® at the University of Missouri’s College of Veterinary Medicine, we are excited to announce that they have agreed to offer Isopet® as a commercially
available therapy option. This makes MU the first regional center to offer Isopet® in addition to our Vista pilot clinic located in the state of WA.
Stock Quote
Links
VIVOS Inc. (OTCQB: RDGL)
719 Jadwin Avenue. Richland, Washington 99352 US
T: 509.736.4000 E: mkorenko@radiogel.com